Cover Image
Market Research Report

Asia Pacific DIABETES DRUGS MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 618293
Published Content info 65 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia Pacific DIABETES DRUGS MARKET FORECAST 2018-2026
Published: April 9, 2018 Content info: 65 Pages
Description

KEY FINDINGS

Global vendors are expanding their business in APAC by establishing their manufacturing facilities in developing countries. As a result, the Asia-Pacific diabetes drug market is expected to exhibit the fastest CAGR of 10.81% over the forecast period of 2018-2026.

MARKET INSIGHTS

Several vendors are focusing on strategic collaborations with domestic distribution partners and suppliers to enhance their distribution and sales channels. The main focus is on Japan, India and China as these countries offer potential opportunities for many global vendors. Additionally, economic development and rise in healthcare spending are expected to further increase the demand for insulin delivery systems in APAC, benefiting the diabetes drug market. In India, diabetes has become a major health problem. Nearly half of the diabetic population goes undetected, resulting in complications at the time of diagnosis. On the other hand, in China, nearly 500 million people are believed to be pre-diabetic, and as a result, today, China is the biggest market for diabetes drugs in the Asia-Pacific market. Thus all these factors are collectively contributing to the APAC diabetes drug market's growth.

COMPETITIVE INSIGHTS

Companies like Pfizer, Sanofi, Eli Lilly And Company, Novo Nordisk A/S, GlaxoSmithKline, Macrogenics Inc, Xoma Corp, AstraZeneca Plc, Xeris Pharmaceuticals, B.Braun Melsungen Ag, Albireo Pharma Inc, Diavacs Inc and Astellas Pharma are operating in this market.

Table of Contents
Product Code: 16325

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. RISING PREVALENCE OF TYPE 2 DIABETES
    • 3.2.2. INSULIN MARKET IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE

4. MARKET DYNAMICS

  • 4.1. ETYMOLOGY OF DIABETES DRUGS MARKET
  • 4.2. MARKET DEFINITION AND SCOPE
  • 4.3. LEGAL, POLICY AND REGULATORY ISSUES
  • 4.4. MARKET DRIVERS
    • 4.4.1. INCREASE IN PREVALENCE OF DIABETES
    • 4.4.2. ADVANCES IN INSULIN TECHNOLOGY
    • 4.4.3. GROWING ELDERLY POPULATION
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
    • 4.5.2. LACK OF AWARENESS AMONG PEOPLE
    • 4.5.3. COST SENSITIVITY ISSUES
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. DEVELOPMENT OF NEW FORMULATIONS
    • 4.6.2. INCREASING RESEARCH AND DEVELOPMENT
  • 4.7. MARKET CHALLENGES
    • 4.7.1. FIERCE MARKET COMPETITION
    • 4.7.2. RISING CONCERNS IN SCIENTIFIC COMMUNITY
    • 4.7.3. GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
    • 4.7.4. POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN

5. MARKET BY DIABETES TYPE

  • 5.1. TYPE 1
  • 5.2. TYPE 2

6. MARKET BY PRODUCT CLASS

  • 6.1. INSULIN
    • 6.1.1. FAST ACTING INSULIN
    • 6.1.2. INTERMEDIATE ACTING INSULIN
    • 6.1.3. LONG-ACTING INSULIN
  • 6.2. NON INSULIN
    • 6.2.1. DPP-4 INHIBITOR
    • 6.2.2. GLP-1 RECEPTORS AGONISTS
    • 6.2.3. SGLT-2 INHIBITORS
    • 6.2.4. OTHERS

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. OPPORTUNITY MATRIX
  • 7.3. VENDOR LANDSCAPE
  • 7.4. PIPELINE ANALYSIS
  • 7.5. KEY BUYING CRITERIA
    • 7.5.1. SAFETY AND EFFICACY
    • 7.5.2. AVAILABILITY
    • 7.5.3. LONG TERM RELIEF
    • 7.5.4. AFFORDABILITY AND COST-EFFECTIVENESS
    • 7.5.5. REIMBURSEMENT OF PRESCRIPTION DRUGS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. ASIA-PACIFIC
    • 8.1.1. CHINA
    • 8.1.2. INDIA
    • 8.1.3. AUSTRALIA
    • 8.1.4. JAPAN
    • 8.1.5. SOUTH KOREA
    • 8.1.6. INDONESIA
    • 8.1.7. MALAYSIA
    • 8.1.8. PHILIPPINES
    • 8.1.9. THAILAND
    • 8.1.10. VIET NAM
    • 8.1.11. REST OF ASIA-PACIFIC

9. COMPANY PROFILES

  • 9.1. ELI LILLY AND COMPANY
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. SWOT ANALYSIS
    • 9.1.4. STRATEGIC INITIATIVES
  • 9.2. ASTRAZENECA PLC.
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. SWOT ANALYSIS
    • 9.2.4. STRATEGIC INITIATIVES
  • 9.3. B.BRAUN MELSUNGEN AG
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SWOT ANALYSIS
    • 9.3.4. STRATEGIC INITIATIVES
  • 9.4. NOVO NORDISK A/S
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. SWOT ANALYSIS
    • 9.4.4. STRATEGIC INITIATIVES
  • 9.5. SANOFI
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SWOT ANALYSIS
    • 9.5.4. STRATEGIC INITIATIVES
  • 9.6. DIAVACS, INC.
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. SWOT ANALYSIS
  • 9.7. XOMA CORP.
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SWOT ANALYSIS
    • 9.7.4. STRATEGIC INITIATIVES
  • 9.8. ALBIREO PHARMA INC.
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SWOT ANALYSIS
  • 9.9. MACROGENICS, INC.
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SWOT ANALYSIS
  • 9.10. ASTELLAS PHARMA
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SWOT ANALYSIS
    • 9.10.4. STRATEGIC INITIATIVES
  • 9.11. GLAXOSMITHKLINE
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SWOT ANALYSIS
  • 9.12. MERCK
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SWOT ANALYSIS
    • 9.12.4. STRATEGIC INITIATIVES
  • 9.13. PFIZER
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SWOT ANALYSIS
    • 9.13.4. STRATEGIC INITIATIVES
  • 9.14. XERIS PHARMACEUTICALS
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SWOT ANALYSIS
    • 9.14.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1: ASIA-PACIFIC DIABETES DRUGS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ BILLION)
  • TABLE 2: REGULATORY FRAMEWORK IN DIABETES DRUGS MARKET
  • TABLE 3: ASIA-PACIFIC DIABETES DRUGS MARKET, BY DIABETES TYPES, 2018-2026, (IN $ BILLION)
  • TABLE 4: ASIA-PACIFIC DIABETES DRUGS MARKET, BY TYPE 1 DIABETES, 2018-2026 (IN $ BILLIONS)
  • TABLE 5: ASIA-PACIFIC DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLIONS)
  • TABLE 6: ASIA-PACIFIC DIABETES DRUGS MARKET, BY PRODUCT CLASS, 2018-2026 (IN $ BILLIONS)
  • TABLE 7: ASIA-PACIFIC DIABETES DRUGS MARKET, BY INSULIN TYPE, 2018-2026, (IN $ BILLION)
  • TABLE 8: ASIA-PACIFIC DIABETES DRUGS MARKET, BY NON INSULIN DRUGS, 2018-2026 (IN $ BILLION)
  • TABLE 9: OPPORTUNITY MATRIX FOR DIABETES DRUGS MARKET
  • TABLE 10: VENDOR LANDSCAPE OF DIABETES DRUGS MARKET
  • TABLE 11: PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 12: ASIA-PACIFIC DIABETES DRUGS MARKET, BY GEOGRAPHY, 2018-2026, (IN $ BILLION)
  • TABLE 13: ASIA-PACIFIC DIABETES DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ BILLION)

LIST OF FIGURES

  • FIGURE 1: ASIA-PACIFIC DIABETES DRUGS MARKET 2018-2026 (IN $ BILLION)
  • FIGURE 2: ASIA-PACIFIC DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 3: ASIA-PACIFIC DIABETES DRUGS MARKET, BY INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 4: AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY CONTINENT AND GENDER (IN YEARS)
  • FIGURE 5: ASIA-PACIFIC DIABETES DRUGS MARKET, BY DIABETES TYPE, 2017 & 2026 (IN %)
  • FIGURE 6: ASIA-PACIFIC DIABETES DRUGS MARKET, BY TYPE 1 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 7: ASIA-PACIFIC DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 8: ASIA-PACIFIC DIABETES DRUGS MARKET, BY PRODUCT CLASS, 2018-2026 (IN $ BILLION)
  • FIGURE 9: ASIA-PACIFIC DIABETES DRUGS MARKET, BY INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 10: ASIA-PACIFIC DIABETES DRUGS MARKET, BY FAST ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 11: ASIA-PACIFIC DIABETES DRUGS MARKET, BY INTERMEDIATE ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 12: ASIA-PACIFIC DIABETES DRUGS MARKET, BY LONG ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 13: ASIA-PACIFIC DIABETES DRUGS MARKET, BY NON-INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 14: ASIA-PACIFIC DIABETES DRUGS MARKET, BY DPP-4 INHIBITOR, 2018-2026 (IN $ BILLION)
  • FIGURE 15: ASIA-PACIFIC DIABETES DRUGS MARKET, BY GLP-1 RECEPTORS AGONISTS, 2018-2026 (IN $ BILLION)
  • FIGURE 16: ASIA-PACIFIC DIABETES DRUGS MARKET, BY SGLT-2 INHIBITORS, 2018-2026 (IN $ BILLION)
  • FIGURE 17: ASIA-PACIFIC DIABETES DRUGS MARKET, BY OTHER NON INSULIN DRUGS, 2018-2026 (IN $ BILLION)
  • FIGURE 18: PORTER'S FIVE FORCE MODEL OF DIABETES DRUGS MARKET
  • FIGURE 19: KEY BUYING IMPACT ANALYSIS
  • FIGURE 20: ASIA-PACIFIC DIABETES DRUGS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
  • FIGURE 21: ASIA-PACIFIC DIABETES DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 22: CHINA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 23: INDIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 24: AUSTRALIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 25: JAPAN DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 26: SOUTH KOREA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 27: INDONESIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 28: MALAYSIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 29: PHILIPPINES DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 30: THAILAND DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 31: VIET NAM DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 32: REST OF ASIA-PACIFIC DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
Back to Top